T cell co-stimulation and in vivo tolerance.
Previous studies have shown that effective T-cell activation requires the engagement of the T-cell receptor complex with MHC-peptide, in parallel with co-stimulation via cell surface adhesion molecules. Blocking these co-stimulatory interactions, in particular the signal transduction via the CD28 molecule, inhibits T-cell activation in vitro and induces T-cell clones into a state of unresponsiveness, termed T-cell anergy. Recent studies have examined the therapeutic effects of treating mice with CD28-B7 antagonists and highlighted the complexity of the CD28 co-stimulatory pathway, as illustrated by the finding that multiple cross-binding ligands for the CD28 and B7 molecules exist that may differentially regulate immune responses.
Lenschow
D J
DJ
Ben May Institute, Department of Pathology and the Committee on Immunology, University of Chicago, Illinois 60637.
Bluestone
J A
JA
D000818:Animals; D018122:B7-1 Antigen / Q000276:immunology; D018106:CD28 Antigens / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D015398:Signal Transduction / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014181:Transplantation Immunology
D018122:B7-1 Antigen; D018106:CD28 Antigens